The role of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in the development of esophageal cancer

Folia Histochemica et Cytobiologica

Volumn 50, Issue 1, 2012, Pages 12-19

  Groblewska, Magdalena ^a   Siewko, Maria ^b   Mroczko, Barbara ^a   Szmitkowski, Maciej ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b Department of Laboratory Diagnostics   (Poland)

Author keywords

Adenocarcinoma of the esophagus; Esophageal squamous cell cancer; Matrix metalloproteinases; Tissue inhibitors of metalloproteinases

Indexed keywords

COLLAGEN TYPE 4; COLLAGENASE 3; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MACROPHAGE ELASTASE; MATRILYSIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE 15; MATRIX METALLOPROTEINASE 16; MATRIX METALLOPROTEINASE 17; MATRIX METALLOPROTEINASE 19; MATRIX METALLOPROTEINASE 20; MATRIX METALLOPROTEINASE 21; MATRIX METALLOPROTEINASE 23; MATRIX METALLOPROTEINASE 26; MATRIX METALLOPROTEINASE 27; MATRIX METALLOPROTEINASE 28; NEUTROPHIL COLLAGENASE; STROMELYSIN; STROMELYSIN 2; STROMELYSIN 3; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TISSUE INHIBITOR OF METALLOPROTEINASE 4; UNCLASSIFIED DRUG;

ANGIOGENESIS; BASEMENT MEMBRANE; CANCER GROWTH; CANCER INCIDENCE; CANCER INVASION; CARCINOGENESIS; DISEASE FREE SURVIVAL; ENZYME ACTIVITY; ENZYME REGULATION; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS CANCER; HUMAN; METASTASIS; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; RISK FACTOR; SQUAMOUS CELL CARCINOMA;

EID: 84860302907     PISSN: 02398508     EISSN: 18975631     Source Type: Journal    
DOI: 10.5603/FHC.2012.0002     Document Type: Review

References (60)

1. Crew KD, Neugut A. Epidemiology of upper gastrointestinal malignancies. Semin Oncol. 2004;31:450-464.
2. Pohn H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst. 2005;97:142-146.
3. Parkin MD, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108.
4. El-Shahat M, Lotfy M, Fahmy L, Abouel-Nour MF, El-Kenawy Ael-M. Prognostic value of microvessel density, matrix metalloproteinase-9 and p53 protein expression in esophageal cancer. J Egypt Natl Cancer Inst. 2004;16:224-230.
5. Vallbohmer D, Lenz HJ. Predictive and prognostic molecular markers in outcome of esophageal cancer. Dis Esophagus. 2006;19:425-432.
6. Lundell LR. Etiology and risk factors for esophageal carcinoma. Dig Dis. 2010;28:641-644.
7. th century. Ann Oncol. 2003;14:v128-149.
8. Holmes RS, Vaughan TL. Epidemiology and pathogenesis of esophageal cancer. Semin Radiat Oncol. 2007;17:2-9.
9. Mayne ST, Navarro SA. Diet, obesity and reflux in the etiology of adenocarcinomas of the esophagus and gastric cardia in humans. J Nutr. 2002;132:3467S-3470S.
10. Lindblad M, Rodriquez LA, Lagergren J. Body mass, tobacco and alcohol and risk of esophageal, gastric cardia and gastric non-cardia adenocarcinoma among males and famales in nested case-control study. Cancer Causes Control. 2005;16:285-294.
11. Fass R, Sampliner RE. Barrett's oesophagus: optimal strategies for prevention and treatment. Drugs. 2003;63:555-564.
12. Hattori S, Muto M, Ohtsu A et al. EMR as salvage treatment for patients with locoregional failure of definitive chemoradiotherapy for esophageal cancer. Gastrointest Endosc. 2003;58:65-70.
13. Chang F, Syrjänen S, Shen Q et al. Evaluation of HPV, CMV, HSV and EBV in esophageal squamous cell carcinomas from a high-incidence area of China. Anticancer Res. 2000;20:3935-3940.
14. Lyronis ID, Baritaki S, Bizakis I, Tsardi M, Spandidos DA. Evaluation of the prevalence of human papillomavirus and Epstein-Barr virus in esophageal squamous cell carcinomas. Int J Biol Markers. 2005;20:5-10.
15. Yao PF, Li GC, Li J et al. Evidence of human papilloma virus infection and its epidemiology in esophageal squamous cell carcinoma. World J Gastroenterol. 2006;12:1352-1355.
16. Brockmann JG, St Nottberg H, Glodny B, Heinecke A, Senninger NJ. CYFRA 21-1 serum analysis in patients with esophageal cancer. Clin Cancer Res. 2000;6:4249-4252.
17. Shimada H, Nabeya Y, Tagawa M et al. Preoperative serum midkine concentration is a prognostic marker for esophageal squamous cell carcinoma. Cancer Sci. 2003;94:628-632.
18. Samantaray S, Sharma R, Chattopadhyaya TK, Gupta SD, Ralhan R. Increased expression of MMP-2 and MMP-9 in esophageal squamous cell carcinoma. J Cancer Res Clin Oncol. 2004;130:37-44.
19. Gu ZD, Li JY, Li M et al. Matrix metalloproteinases expression correlates with survival in patients with esophageal squamous cell carcinoma. Am J Gastroenterol. 2005;100:1835-1843.
20. Woessner JF Jr. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J. 1991;5:2145-2154.
21. Werb Z, Ashkenas J, MacAuley A, Wiesen JF. Extracellular matrix remodeling as a regulator of stromal-epithelial interactions during mammary gland development, involution and carcinogenesis. Braz J Med Biol Res. 1996;29:1087-1097.
22. Ii M, Yamamoto H, Adachi Y, Maruyama Y, Shinomura Y. Role of matrix metalloproteinase-7 (matrilysin) in human cancer invasion, apoptosis, growth, and angiogenesis. Exp Biol Med. 2006;231:20-27.
23. O'Byrne EM, Parker DT, Roberts ED et al. Oral administration of a matrix metalloproteinase inhibitor, CGS 27023A, protects the cartilage proteoglycan matrix in a partial meniscectomy model of osteoarthritis in rabbits. Inflamm Res. 1995;44:S117-118.
24. Cawston TE. Metalloproteinase inhibitors and the prevention of connective tissue breakdown. Pharmacol Ther. 1996;70:163-182.
25. Saarialho-Kere UK, Vaalamo M, Puolakkainen P, Airola K, Parks WC, Karjalainen-Lindsberg ML. Enhanced expression of matrilysin, collagenase, and stromelysin-1 in gastrointestinal ulcers. Am J Pathol. 1996;148:519-526.
26. Rosenberg GA. Matrix metalloproteinases in brain injury. J Neurotrauma. 1995;12:833-842.
27. Chandler S, Coates R, Gearing A, Lury J, Wells G, Bone E. Matrix metalloproteinases degrade myelin basic protein. Neurosci Lett. 1995;201:223-226.
28. Woessner JF. The matrix metalloproteinase family. In: Parks WC, Mecham RP, eds. Matrix metalloproteinases. Academic Press, 1998:1-14.
29. Thompson RW, Parks WC. Role of matrix metalloproteinases in abdominal aortic aneurysms. Ann NY Acad Sci. 1996;800:157-174.
30. Strauss BH, Robinson R, Batchelor WB et al. In vivo collagen turnover following experimental balloon angioplasty injury and the role of matrix metalloproteinases. Circ Res. 1996;79:541-550.
31. Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson UP. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol. 1997;74:111-122.
32. Wilhelm SM, Collier IE, Marmer BL, Eisen AZ, Grant GA, Goldberg GI. SV40-transformed human lung fibroblasts secrete a 92-kDa type IV collagenase which is identical to that secreted by normal human macrophages. J Biol Chem. 1989;264:17213-17221.
33. Goldberg GI, Marmer BL, Grant GA, Eisen AZ, Wilhelm S, He CS. Human 72-kilodalton type IV collagenase forms a complex with a tissue inhibitor of metalloproteases designated TIMP-2. Proc Natl Acad Sci USA. 1989;86:8207-8211.
34. Bigg HF, Shi YE, Liu YE, Steffensen B, Overall CM. Specific, high affinity binding of tissue inhibitor of metalloproteinases-4 (TIMP-4) to the COOH-terminal hemopexin-like domain of human gelatinase A. TIMP-4 binds progelatinase A and the COOH-terminal domain in a similar manner to TIMP-2. J Biol Chem. 1997;272:15496-15500.
35. Apte SS, Olsen BR, Murphy G. The gene structure of tissue inhibitor of metalloproteinases (TIMP)-3 and its inhibitory activities define the distinct TIMP gene family. J Biol Chem. 1996;270:14313-14318.
36. Martin DC, Ruther U, Sanchez-Sweatman OH, Orr FW, Khokha R. Inhibition of SV40 T antigen-induced hepatocellular carcinoma in TIMP-1 transgenic mice. Oncogene. 1996;13:569-576
37. Anand-Apte B, Pepper MS, Voest E et al. Inhibition of angiogenesis by tissue inhibitor of metalloproteinase-3. Invest Ophthalmol Vis Sci. 1997;38:817-823.
38. Ahonen M, Baker AH, Kahari VM. Adenovirus-mediated gene delivery of tissue inhibitor of metalloproteinases-3 inhibits invasion and induces apoptosis in melanoma cells. Cancer Res. 1998;58:2310-2315.
39. Zeng ZS, Cohen AM, Guillem JG. Loss of basement membrane type IV collagen is associated with increased expression of metalloproteinases 2 and 9 (MMP-2 and MMP-9) during human colorectal tumorigenesis. Carcinogenesis. 1999;20:749-755.
40. Talvensaari-Mattila A, Paakko P, Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinoma. Br J Cancer. 2003;89:1270-1275.
41. Kubben FJ, Sier CF, Meijer MJ et al. Clinical impact of MMP and TIMP gene polymorphisms in gastric cancer. Br J Cancer. 2006;95:744-751.
42. Giannopoulos G, Pavlakis K, Parasi A et al. The expression of matrix metalloproteinases-2 and-9 and their tissue inhibitor 2 in pancreatic ductal and ampullary carcinoma and their relation to angiogenesis and clinicopathological parameters. Anticancer Res. 2008;28:1875-1881.
43. Murnane MJ, Cai J, Shuja S, McAneny D, Klepeis V, Willett JB. Active MMP-2 effectively identifies the presence of colorectal cancer. Int J Cancer. 2009;125:2893-2902.
44. Murray GI, Duncan ME, O'Neil P, McKay JA, Melvin WT, Fothergill JE. Matrix metalloproteinase-1 is associated with poor prognosis in oesophageal cancer. J Pathol. 1998;185:256-261.
45. Tanioka Y, Yoshida T, Yagawa T et al. Matrix metalloproteinase-7 and matrix metalloproteinase-9 are associated with unfavourable prognosis in superficial oesophageal cancer. Br J Cancer. 2003;89:2116-2121.
46. Mroczko B, Kozłowski M, Groblewska M et al. The diagnostic value of the measurement of matrix metalloproteinase 9 (MMP-9), squamous cell cancer antigen (SCC) and carcinoembryonic antigen (CEA) in the sera of esophageal cancer patients. Clin Chim Acta. 2008;389:61-66.
47. Mroczko B, Kozłowski M, Groblewska M et al. Expression of matrix metalloproteinase-9 in the neoplastic and interstitial inflammatory infiltrate cells in the different histopathological types of esophageal cancer. Folia Histochem Cytobiol. 2008;46:471-478.
48. Koyama H, Iwata H, Kuwabara Y, Iwase H, Kobayashi S, Fujii Y. Gelatinolytic activity of matrix metalloproteinase-2 and-9 in oesophageal carcinoma: a study using in situ zymography. Eur J Cancer. 2000;36:2164-2170.
49. Augoff K, Grabowski K, Rabczynski J, Kolondra A, Tabola R, Sikorski AF. Expression of decorin in esophageal cancer in relation to the expression of three isoforms of transforming growth factor-beta (TGF-beta1,-beta2, and-beta3) and matrix metalloproteinase-2 activity. Cancer Invest. 2009;27:443--452.
50. Li Y, Ma J, Guo Q et al. Overexpression of MMP-2 and MMP-9 in esophageal squamous cell carcinoma. Dis Esophagus. 2009;22:664-667.
51. Ishibashi Y, Matsumoto T, Niwa M et al. CD147 and matrix metalloproteinase-2 protein expression as significant prognostic factors in esophageal squamous cell carcinoma. Cancer. 2004;101:1994-2000.
52. Grimm M, Lazariotou M, Kircher S et al. MMP-1 is a (pre) invasive factor in Barrett-associated esophageal adenocarcinomas and is associated with positive lymph node status. J Transl Med. 2010;8:99-110.
53. Mukherjee S, Roth MJ, Dawsey SM et al. Increased matrix metalloproteinase activation in esophageal squamous cell carcinoma. J Transl Med. 2010;8:91-97.
54. Chen L, Di D, Luo G et al. Immunochemical staining of MT2--MMP correlates positively to angiogenesis of human esophageal cancer. Anticancer Res. 2010;30:4363-4368.
55. Chen YK, Chang WS, Wu IC et al. Molecular characterization of invasive subpopulations from an esophageal squamous cell carcinoma cell line. Anticancer Res. 2010;30:727-736.
56. Sharma R, Chattopadhyay TK, Mathur M, Ralhan R. Prognostic significance of stromelysin-3 and tissue inhibitor of matrix metalloproteinase-2 in esophageal cancer. Oncology. 2004;3-4:300-309.
57. Vegh I, Santiuste AD, Colina F et al. Relationship between biomarker expression and allelic alteration in esophageal carcinoma. J Gastroenterol Hepatol. 2007;22:2303-2309.
58. Mori M, Mimori K, Sadanaga N et al. Prognostic impact of tissue inhibitor of matrix metalloproteinase-1 in esophageal carcinoma. Int J Cancer. 2000;88:575-578.
59. Salmela MT, Karjalainen-Lindsberg ML, Puolakkainen P, Saarialho-Kere U. Upregulation and differential expression of matrilysin (MMP-7) and metalloelastase (MMP-12) and their inhibitors TIMP-1 and TIMP-3 in Barrett's oesophageal adenocarcinoma. Br J Cancer. 2001;85:383-392.
60. Miyazaki T, Kato H, Nakajima M et al. An immunohistochemical study of TIMP-3 expression in oesophageal squamous cell carcinoma. Br J Cancer. 2004;91:1556-1560.